Chevy Chase, MD, United States
Chevy Chase, MD, United States
SEARCH FILTERS
Time filter
Source Type

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. The personalized medicine (global & USA) market is presented as follows: By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) By Therapy (Cancer, Cardiovascular, Infectious Disease) Key Opinion Leaders that contributed to interview questions within the report include: - Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group - Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland - Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC - Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland - Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine - Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine - David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine - Deborah Phippard, PhD, Vice President, Research, Precision for Medicine - Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine A wealth of financial data & business strategy information is provided including: - Company financials, sales & revenue figures - Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies - Business Model Strategies for Providers. Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) - Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: - Key strengths, weaknesses and threats influencing leading player position within the market - Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) - Top fastest growing market segments and emerging opportunities - Top pharmaceutical companies within the IPM by market share and revenue - Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos - Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) - CE-marked Personalized Medicine/Diagnostic Tests - FDA Advances in Personalized Medicine Regulation What you will gain: - An in-depth understanding of the global personalized medicine market and it's environment - Current market facts, figures and product lines of key players in the industry - Emerging trends in key markets such as the US, UK, Germany and France - Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing - Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies - FDA approved pharmacogenetic tests and recognized biomarkers - Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry This report tackles key concerns to the personalized medicine market such as: - Lack of regulatory policy and legislation in the US and Europe - Reimbursement schemes and payers concerns - Transition of investigational diagnostic assays and therapeutics to clinical practice - Direct to consumer (DTC) test kits and implications for the public This report will tell you if the companies mentioned are: - Strong, competitive players - Pooling their resources for specific growth and therapeutic areas - Investing strategically in R&D - Have a history of strategic M&A activity Key Topics Covered: 1.0 Executive Summary 2.0 Introduction and Background 3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics 4.0 Personalized Medicine and Integration into the Healthcare System 5.0 Private and Public Funding and Personalized Medicine Reimbursement 6.0 European Personalized Medicine Market - Payments and Investment 7.0 Personalized Medicine -Business Model Analysis 8.0 Personalized Medicine Main Industry Players 9.0 Personalized Medicine Market Analysis 10.0 Strengths and Advantages of Personalized Medicine 11.0 Restraints of the Personalized Medicine Market 12.0 Personalized Medicine and Regulatory Policies 13.0 Final Summary and Future Perspectives 14.0 Interviews with Key Opinion Leaders Companies Mentioned For more information about this report visit http://www.researchandmarkets.com/research/wk98zk/personalized Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-personalized-medicine-targeted-therapeutics-and-companion-diagnostic-market-2017-2021-strategic-analysis-of-industry-trends-technologies-participants-and-environment---research-and-markets-300460730.html


Dublin, May 24, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2021- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine (global & USA) market is presented as follows: By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) By Therapy (Cancer, Cardiovascular, Infectious Disease) Key Opinion Leaders that contributed to interview questions within the report include: - Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group - Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland - Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC - Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland - Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine - Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine - David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine - Deborah Phippard, PhD, Vice President, Research, Precision for Medicine - Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine A wealth of financial data & business strategy information is provided including: - Company financials, sales & revenue figures - Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies - Business Model Strategies for Providers. Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) - Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: - Key strengths, weaknesses and threats influencing leading player position within the market - Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) - Top fastest growing market segments and emerging opportunities - Top pharmaceutical companies within the IPM by market share and revenue - Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos - Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) - CE-marked Personalized Medicine/Diagnostic Tests - FDA Advances in Personalized Medicine Regulation This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. What you will gain: - An in-depth understanding of the global personalized medicine market and it's environment - Current market facts, figures and product lines of key players in the industry - Emerging trends in key markets such as the US, UK, Germany and France - Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing - Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies - FDA approved pharmacogenetic tests and recognized biomarkers - Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry This report tackles key concerns to the personalized medicine market such as: - Lack of regulatory policy and legislation in the US and Europe - Reimbursement schemes and payers concerns - Transition of investigational diagnostic assays and therapeutics to clinical practice - Direct to consumer (DTC) test kits and implications for the public Who should read this report? - Pharmaceutical, biotechnology and diagnostic companies (CEOs, VPs, Business Development, C-Suite)with an interest in personalized medicine - Industry professionals and business strategists will discover key information to propel their policies - Investors will gain inside information to dominant players in the industry and future forecasts - Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment This report will tell you if the companies mentioned are: - Strong, competitive players - Pooling their resources for specific growth and therapeutic areas - Investing strategically in R&D - Have a history of strategic M&A activity Key Topics Covered: 1.0 Executive Summary 2.0 Introduction and Background 3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics 4.0 Personalized Medicine and Integration into the Healthcare System 5.0 Private and Public Funding and Personalized Medicine Reimbursement 6.0 European Personalized Medicine Market - Payments and Investment 7.0 Personalized Medicine -Business Model Analysis 8.0 Personalized Medicine Main Industry Players 14.0 Interviews with Key Opinion Leaders Companies Mentioned - 23andMe - Abbott Laboratories - Abbott Molecular Inc. - Admera Health (GENEWIZ) - Affymetrix - Agendia - Alere - Amgen - Astex Pharmaceuticals - AstraZeneca - Atossa Genetics - Becton Dickenson - bioMerieux - BristolMyersSquibb - Cancer Genetics - Celera (Quest Diagnostics) - Celldex Therapeutics - Claritas Genomics - CuraGen - Danaher (Leica Biosystems) - deCode Genetics (Amgen) - EDP Biotech - ELDA BioTech - Eisai - Eli Lilly - Foundation Medicine - Genelex - GlaxoSmithKline - HalioDx - Human Longevity Inc (Cypher Genomics) - Ikonisys - Illumina - InterGenetics - Johnson & Johnson - LabCorp - Life Technologies - MDxHealth - Merck - MolecularMD Corporation - Monogram Biosciences - Myriad - NanoString Technologies - Nodality - Novartis MDx - Orion Genomics - Oxford BioTherapeutics - Pfizer - Qiagen - Roche Molecular Diagnostics - Sanofi - SensiGen - Siemens Healthcare Diagnostics - Takeda - Thermo Fisher Scientific - Transgenomic - Ventana (Roche) - Vermillion (Ciphergen) - Vertex Pharmaceuticals For more information about this report visit http://www.researchandmarkets.com/research/zbw7h4/personalized


News Article | February 15, 2017
Site: globenewswire.com

WINNIPEG, Manitoba, Feb. 15, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce that Harry Glorikian has joined its Business Advisory Board. Mr. Glorikian has over 30 years of private and public company success in the biomedical and life sciences industries. He is recognized as a global innovator with high-profile consulting, executive and board experience and a passion for data driven medical diagnostics. Mr. Glorikian’s notable recent experience includes roles as Entrepreneur in Residence to GE Ventures – New Business Creation Group and as a member of the board of directors of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Nucelis (a gene-editing industrial biotech company) and Evidation Health (a digital health startup launched with support from GE Ventures). He is also a co-founder and an advisory board member of DrawBridge Health (a diagnostics startup launched with support from GE Ventures). Previously Mr. Glorikian co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories. “With the addition of Harry Glorikian to the Business Advisory Board, 3DS has gained tremendous insight into the development and commercialization of cutting-edge medical diagnostics,” noted Jason Flowerday, CEO of 3DS. “Mr. Glorikian has a track record of innovation and commercial success. His addition to the team is a very positive step forward for 3DS.” Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University. He has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets. Mr. Glorikian is also author of the recently published and highly-relevant book, “Commercializing Novel IVDs: A Comprehensive Manual for Success.” An IVD is an in-vitro diagnostic device which is the type of diagnostic tool that 3DS is currently developing. Mr. Glorikian’s unique manual provides an overview of the major components to IVD development, from product conception through commercialization. His understanding of the diagnostic commercialization process in the context of clinical utility and cost effectiveness is an enormous asset to 3DS. 3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 20 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com. This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Dublin, May 24, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2021- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine (global & USA) market is presented as follows: By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) By Therapy (Cancer, Cardiovascular, Infectious Disease) Key Opinion Leaders that contributed to interview questions within the report include: - Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group - Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland - Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC - Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland - Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine - Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine - David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine - Deborah Phippard, PhD, Vice President, Research, Precision for Medicine - Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine A wealth of financial data & business strategy information is provided including: - Company financials, sales & revenue figures - Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies - Business Model Strategies for Providers. Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) - Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: - Key strengths, weaknesses and threats influencing leading player position within the market - Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) - Top fastest growing market segments and emerging opportunities - Top pharmaceutical companies within the IPM by market share and revenue - Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos - Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) - CE-marked Personalized Medicine/Diagnostic Tests - FDA Advances in Personalized Medicine Regulation This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. What you will gain: - An in-depth understanding of the global personalized medicine market and it's environment - Current market facts, figures and product lines of key players in the industry - Emerging trends in key markets such as the US, UK, Germany and France - Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing - Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies - FDA approved pharmacogenetic tests and recognized biomarkers - Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry This report tackles key concerns to the personalized medicine market such as: - Lack of regulatory policy and legislation in the US and Europe - Reimbursement schemes and payers concerns - Transition of investigational diagnostic assays and therapeutics to clinical practice - Direct to consumer (DTC) test kits and implications for the public Who should read this report? - Pharmaceutical, biotechnology and diagnostic companies (CEOs, VPs, Business Development, C-Suite)with an interest in personalized medicine - Industry professionals and business strategists will discover key information to propel their policies - Investors will gain inside information to dominant players in the industry and future forecasts - Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment This report will tell you if the companies mentioned are: - Strong, competitive players - Pooling their resources for specific growth and therapeutic areas - Investing strategically in R&D - Have a history of strategic M&A activity Key Topics Covered: 1.0 Executive Summary 2.0 Introduction and Background 3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics 4.0 Personalized Medicine and Integration into the Healthcare System 5.0 Private and Public Funding and Personalized Medicine Reimbursement 6.0 European Personalized Medicine Market - Payments and Investment 7.0 Personalized Medicine -Business Model Analysis 8.0 Personalized Medicine Main Industry Players 14.0 Interviews with Key Opinion Leaders Companies Mentioned - 23andMe - Abbott Laboratories - Abbott Molecular Inc. - Admera Health (GENEWIZ) - Affymetrix - Agendia - Alere - Amgen - Astex Pharmaceuticals - AstraZeneca - Atossa Genetics - Becton Dickenson - bioMerieux - BristolMyersSquibb - Cancer Genetics - Celera (Quest Diagnostics) - Celldex Therapeutics - Claritas Genomics - CuraGen - Danaher (Leica Biosystems) - deCode Genetics (Amgen) - EDP Biotech - ELDA BioTech - Eisai - Eli Lilly - Foundation Medicine - Genelex - GlaxoSmithKline - HalioDx - Human Longevity Inc (Cypher Genomics) - Ikonisys - Illumina - InterGenetics - Johnson & Johnson - LabCorp - Life Technologies - MDxHealth - Merck - MolecularMD Corporation - Monogram Biosciences - Myriad - NanoString Technologies - Nodality - Novartis MDx - Orion Genomics - Oxford BioTherapeutics - Pfizer - Qiagen - Roche Molecular Diagnostics - Sanofi - SensiGen - Siemens Healthcare Diagnostics - Takeda - Thermo Fisher Scientific - Transgenomic - Ventana (Roche) - Vermillion (Ciphergen) - Vertex Pharmaceuticals For more information about this report visit http://www.researchandmarkets.com/research/zbw7h4/personalized

Loading Precision for Medicine collaborators
Loading Precision for Medicine collaborators